Company Description
ETHZilla Corporation, a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States.
The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain.
The company was formerly known as 180 Life Sciences Corp. and changed its name to ETHZilla Corporation in August 2025.
ETHZilla Corporation is headquartered in Palm Beach, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Lloyd Jordan |
Contact Details
Address: 2875 South Ocean Blvd, Suite 200 Palm Beach, Florida 33480 United States | |
| Phone | 650 507 0669 |
| Website | ethzilla.com |
Stock Details
| Ticker Symbol | ETHZW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
Key Executives
| Name | Position |
|---|---|
| Sir Marc Feldman Ph.D. | Co-Founder |
| McAndrew Rudisill BA(Econ) | Executive Chairman |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder and Chairman of Clinical Advisory Board |
| Eric R. Van Lent | CAO, Principal Accounting and Financial Officer |